The purpose of this proof of concept study is to provide COVID-19 convalescent plasma to patients with moderate to severe COVID-19 and assess: - the titer of anti-COVID-19 antibodies in the donors and in the patients before and after treatment; - the in-depth analysis of immunological parameters in the donors and in recipient before and after treatment; - the impact of plasma transfusion on the reduction of viral load and inflammation - safety and tolerability - clinical efficacy
Biological: Blood plasma
Convalescent plasma after COVID-19
Inclusion Criteria:
- Hospitalized adult patients 18 - 75 y.o. with confirmed COVID-19 infection by
nasopharyngeal swab;
- radiologically confirmed pneumonia;
- SpO2 > 92o/o and < 96% (room air);
- ongoing thromboembolic prophylaxis.
Exclusion Criteria:
- Participation to another COVID-19 trial;
- severe COVID-19 disease (SpO2 < 93o/o in room air);
- severe allergic transfusion reactions or anaphylaxis in the patient history;
- documented lgA deficiency;
- unstable heart disease with signs of circulatory overload;
- malignancies or other concomitant diseases with poor short-term prognosis;
- pregnancy.
Ospedale Regionale Locarno
Locarno, Ticino, Switzerland
Stefano Fontana, M.D., Principal Investigator
Servizio Trasfusionale, Lugano